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Background: Protein Structure Initiative:Biology (PSI:Biology) is the third phase of PSI where protein structures are
determined in high-throughput to characterize their biological functions. The transition to the third phase entailed
the formation of PSI:Biology Partnerships which are composed of structural genomics centers and biomedical
science laboratories. We present a method to examine the impact of protein structures determined under the
auspices of PSI:Biology by measuring their rates of annotations. The mean numbers of annotations per structure
and per residue are examined. These are designed to provide measures of the amount of structure to function
connections that can be leveraged from each structure.
Results: One result is that PSI:Biology structures are found to have a higher rate of annotations than structures
determined during the first two phases of PSI. A second result is that the subset of PSI:Biology structures
determined through PSI:Biology Partnerships have a higher rate of annotations than those determined exclusive of
those partnerships. Both results hold when the annotation rates are examined either at the level of the entire
protein or for annotations that are known to fall at specific residues within the portion of the protein that has a
determined structure.
Conclusions: We conclude that PSI:Biology determines structures that are estimated to have a higher degree of
biomedical interest than those determined during the first two phases of PSI based on a broad array of biomedical
annotations. For the PSI:Biology Partnerships, we see that there is an associated added value that represents part of
the progress toward the goals of PSI:Biology. We interpret the added value to mean that team-based structural
biology projects that utilize the expertise and technologies of structural genomics centers together with biological
laboratories in the community are conducted in a synergistic manner. We show that the annotation rates can be
used in conjunction with established metrics, i.e. the numbers of structures and impact of publication records, to
monitor the progress of PSI:Biology towards its goals of examining structure to function connections of high
biomedical relevance. The metric provides an objective means to quantify the overall impact of PSI:Biology as it
uses biomedical annotations from external sources.
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Protein Structure Initiative: Biology (PSI:Biology) deter-
mines the structures of proteins on a large scale to re-
veal their biological functions. Scientific partnerships
(PSI:Biology Partnerships) are formed between scientists
in the structural genomics centers and those in bio-
logical laboratories of the community. Through the work
of the partnerships, broad and challenging biological
questions are addressed [1]. Example areas of study in-
clude metagenomics and microbiomes, whole genomes
of organisms and organelles, and proteins along path-
ways as described by systems biology approaches. The
technologies and expertise available in the structural
genomics centers enable protein structures to be deter-
mined in high-throughput [2,3].
Systematic approaches are utilized for structure deter-
mination through the PSI, and the methodological
pipeline starts with the selection of protein targets [4,5].
Summaries of the target selection processes are de-
scribed in the Structural Biology Knowledgebase [6].
One approach to target selection is to choose represen-
tative sequences from protein families. An example ap-
plication of that approach is to obtain the structures of
unique folds. That application has been demonstrated
through the attainment of representative structures of
proteins with unknown folds, as was done in the first
two phases of PSI (PSI:1&2). The project is subsequently
continued into the third phase of PSI, PSI:Biology.
The resultant structures of unique protein folds are
used directly in further studies or they are leveraged to
obtain homology models of proteins which have no
known structure. Applications that are enabled include
computational studies such as the interactions with ligands
or drugs [7-9]. Computational studies to characterize the
proteins are thereby supported by PSI. Follow-on experi-
mental studies are supported through the provision of the
DNA clones of the determined structures, as available
through the Materials Repository [10].
There are a proportionate number of follow-on func-
tional characterization studies that are performed by the
broader scientific community after determination of protein
structures by the PSI [11]. But there is a latency in these
functional characterization studies that reflects the natural
pace at which these studies are undertaken and completed.
With the entrance of PSI:Biology, there is now more par-
ticipation of scientists from the biomedical community
studying the functions of the structures. This is done in a
coordinated manner and it is subject to the NIH peer-
review process of partnership formation. The resultant PSI:
Biology Partnerships direct structural projects from start to
finish with regard to the selection of targets and the con-
current functional characterization studies.
The overall impact of the structural results of PSI for
the biomedical community at large is monitored andassessed in part by accounting for the total number of
structures determined. A corresponding online metrics
site lists the resultant numbers of structures [12]. For
the structures determined through PSI:Biology, the user
can examine the numbers of structures represented for
different phyla and organisms, e.g. eukaryotic, prokary-
otic, and human proteins. The metrics site also lists the
number of PSI:Biology publications, citations, and total
journal impact. These can also be used as measures of
the biomedical importance of the research being done in
PSI:Biology. These measures account for some of the
information that is generated through the PSI. But sum-
maries regarding the specific functions of the deter-
mined structures, as assessed by external biomedical
resources, are necessary. These external measures pro-
vide a further understanding of the focus and depth of
the structure to function relationships that have been
characterized.
In the current study, we describe the biological rele-
vance of the structures determined through PSI:Biology
to estimate the relative impact that the project has for
the elucidation of structure to function relationships. A
protein here is viewed as having higher biological rele-
vance if it has been studied to a greater extent by the
biomedical community. The annotations used in the
study are those that represent biological functions that
can be attributed to more than one protein. The relative
impact of PSI:Biology is quantified using the objective
measures of the rates of annotation assignments made
by biomedical resources that are external to PSI.
We utilize protein knowledgebases that comprehen-
sively integrate and describe the broad array of biological
functions of proteins. The UniProt knowledgebase is
used, which characterizes protein sequences on the
scales of all known proteomes [13,14]. Also used are the
functional annotations obtained through the Structural
Biology Knowledgebase (SBKB) from sources external to
PSI [6,15]. These annotations and others from open
sources described herein provide a perspective regarding
the wide range of functions that are attributed to the de-
termined protein structures.
To see the relative impact of PSI:Biology, we examine
the average rates at which annotations are assigned to
PSI:Biology structures relative to other structural pro-
jects. One comparison is for PSI:Biology relative to
PSI:1&2. A second is for structures determined through
the PSI:Biology Partnerships as compared to structures
determined by US authors in which they do not partici-
pate in such partnerships.
Results and discussion
Comparison of PSI:1&2 to PSI:Biology
For this comparison, we measure the impact of PSI:Biology
relative to PSI:1&2 to see the differences in the trends of
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potential impact of PSI:Biology structures with those com-
ing from PSI:1&2. Specifically, we calculated the ratios of
the mean number of assignments per structure for a range
of annotations from multiple data sources. PSI:Biology
structures are more highly annotated across most of the
resources that describe functional and phenotypic associa-
tions. These results are statistically significant as judged by
the Student’s t-test (p-value ≤ 0.05). For example, PSI:
Biology structures are relatively more highly annotated
in the Orphanet resource, (p-value < 0.001), a resource
that describes associations of proteins with rare disease
[16]. From the perspective of annotations assigned to
particular residues within the structures, we also see
that rates of PSI:Biology are higher than PSI:1&2. See
Figure 2. These results support the assertion that
PSI:Biology has focused on structure determinations
of higher biomedical interest than those examined
during PSI:1&2. See Additional file 1: Tables S1 and S2
for the data used in the plots.
As assessed from the perspective of a broad spectrum
of biomedical annotations shown, most annotation as-






































































Figure 1 Ratios of mean number of annotation assignments per prot
that on average there are more annotation assignments per protein structu
Additional file 1: Table S1. Inset- Ratios for a representative groups of annorelative to PSI:1&2. The types of functions well
represented in PSI:Biology tend to be those that are
associated with higher order biological processes ra-
ther than molecular level functions. For example, we
see that Gene Ontology biological processes and
UniProt disease keyword annotations are greater for
PSI:Biology, but the rate of Gene Ontology mole-
cular functions is lower. We also see a greater per-
centage of mammalian and human source organism
assignments when viewing the organism annotations
for PSI:Biology relative to PSI:1&2. We infer that
this higher representation of complex biology char-
acterizes PSI:Biology.
The numbers of structures served as a metric for the
first two phases of PSI, PSI:1 and PSI:2. It measured the
progress toward the goals of these phases which in-
cluded the development of methods for high-throughput
structure determination and the determination protein
structures that address different protein sequence fam-
ilies. The metric is applied for PSI:Biology where struc-
tures are determined in high throughput using the
methods, coordination, and expertise developed during
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Ratio (PSI:Biology / PSI:1&2)
1.513TOTAL
Figure 2 Ratios of mean number of UniProt annotation
assignments per residue from PSI:Biology versus PSI:1&2. The
plot shows the ratios of the mean numbers of UniProt annotation
assignments per residue for proteins addressed in all PSI:Biology
projects versus all PSI:1&2 projects. Data for the plot is available in
Additional file 1: Table S2. A ratio greater than 1 indicates that on
average there are more assignments per residue for that annotation
type in PSI:Biology as compared to PSI:1&2.
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which high throughput is sustained, but it does not ad-
dress all the progress towards its goals of determining
biomedically relevant structure to function connections.
The inference is made based on the result that there are
a greater number of annotation rates that are higher in
PSI:Biology compared to PSI:1&2. To more fully address
the progress, we introduce the annotation metric as a
way to more fully capture the numbers of structure to
function connections addressed in PSI:Biology. As ap-
plied, it is an objective metric since it utilizes annota-
tions of function that are made by biomedical sources
that are external to PSI.
The annotation metric assesses a broad range of
functions and can be viewed as a complement to
the established metric of counting the numbers ofstructures. Further, it is complementary to another
established metric of the impact of PSI that is based on
the corresponding publication records of the structures.
These are described in the SBKB’s publication portal [6].
We see that the annotation metric can be considered in
the context of the established metrics. For example,
there are proteins that are biologically relevant that have
yet to be studied to great extent by the scientific com-
munity, such as those developed through protein design
[17]. These proteins will have a low number of annota-
tions yet they will maintain a relatively high biomedical
relevance. A more optimal measure of impact for such
structures may be based on their corresponding publica-
tion records. Also an additional measure of the rate of
follow-on studies based on the structure is to be consid-
ered. One such measure has been developed to examine
PSI-2 structures [11], and may continue to be applied to
PSI:Biology structures. We see that the publication re-
cords, numbers of structures metric, and annotation
metric provide complementary perspectives regarding
the impact of PSI:Biology.Comparison of PSI:Biology Partnerships to US
non-SG ensemble
We next compare structures determined as a result of the
PSI:Biology Partnerships to non-structural genomics struc-
tures determined by US authors available from the PDB
(PDB US non-SG ensemble). There are 117 structures iden-
tified as resulting from PSI:Biology Partnerships, and 5613
structures are identified in the US non-SG ensemble. A
stated goal in the composition of the PSI:Biology Partner-
ships is to determine protein structures that address broad,
challenging biological questions [1,6]. These projects are
subject to the NIH peer-review process. The comparison
set is the US non-SG ensemble, which represents all
structures determined by US authors exclusive of structural
genomics.
Figure 3 shows that the Partnership structures tend to
have higher annotation rates than structures from the
PDB US non-SG ensemble. For the comparison, we see
that there is a focus on higher order biological processes
and diseases. One illustrative example is a higher focus
on signaling pathways related to human cancer, as
exhibited in the representation of proteins in the Na-
tional Cancer Institute’s Pathway Interaction Database
[18]. A second illustrative example is a greater focus on
coding sequence diversity, which includes complex an-
notations of splice variants [19]. UniProt domains are
also higher, which indicates a focus on biologically rele-
vant domains. Noteworthy exceptions are enzymes, an-
notated with EC numbers, and relevant ligands, as
suggested by BioCyc small molecule entries. We inter-
pret this finding as a result of a selection bias against
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Figure 3 Ratios of mean number of annotation assignments per protein from PSI:Biology Partnerships versus the PDB US non-SG
ensemble. Asterisks indicate the annotation ratios that are statistically significant based on a Student’s t-test (p-value≤ 0.05). Data for the plot is
available in Additional file 1: Table S3. Inset- Ratios for a group of annotations based on the UniProt keyword system.
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Additional file 1: Table S3 for data used in Figure 3.
There is a separate structural genomics initiative that
focuses on enzymes [20], which was excluded from the
US non-structural genomics PDB ensemble. Thus, there
appears to be higher emphasis on biological relevance in
PSI:Biology Partnership structures versus US, non-
structural genomics structures in the PDB. We believe
that most of the US, non-structural genomics structures
in the PDB represent structures determined under the
auspices of individual investigator funding mechanisms
(i.e., primarily R01 funded structure determinations).
For the comparison between PSI:Biology Partnerships
and the PDB subset, the mean number of annotation
assignments for a representative group of annotation
types based on the UniProt keyword system is also ex-
amined [13]. See Figure 3, inset. These keywords address
different types of functions of proteins and aid in the
reduction of redundancy in the data. They also have the
quality of being manually reviewed (those with UniProtKB/
Swiss-Prot entries) or assigned by rules (those with
UniProtKB/Tremble entries) [21]. The UniProt keyword
annotations were normalized according to their relative oc-
currence, and the average of the normalized annotation
rates were used to estimate an overall degree to which a
protein structure is annotated. This comparison indicatesthat there are approximately 30% more annotations per
protein on average when comparing PSI Biology Partner-
ship structures to the structures from the PDB US non-SG
ensemble. Analyses of the average ratios and the normal-
ized ratios indicate that they are statistically different
between these groups. See Table 1.
We also see that the rates of the residue annotation
assignments based on the UniProt system further sup-
port the finding that there is approximately a 1.3 times
higher assignment rate for PSI:Biology Partnership struc-
tures relative to the PDB US non-SG ensemble. The
residue assignments are based on UniProt’s system of
identifying sequence features. We view these residue
level assignments as addressing different functions, and
we see that they can be accumulated at the same scale
to give an overall assignment rate per residue for each
data set. See Figure 4 with the supplementary data pro-
vided in Additional file 1: Table S4. As a further test, we
excluded the annotation types that we regarded as largely
computational derived, e.g. Compositional bias, Transmem-
brane, Coiled coil, Domain, Repeat, Signal, and Zinc finger.
The results show that annotation rates for the residue level
assignments for PSI:Biology Partnerships are higher than
for the PDB US non-SG ensemble, p-value = 2.9×10-30.
The highest rate difference for the residue level assign-
ments was for Transit peptide. That makes sense given
Table 1 Mean numbers of annotation assignments per protein for eight representative annotation types
PDB PSI:Biology
PDB PSI:Biology US non-SG Partnerships
US non-SG Partnerships Ratio of Normalized Normalized
Annotation type Means Means Means Means Means
GO biological process 4.385 5.802 1.323 1.359 1.798
GO cellular component 1.889 1.765 0.934 1.327 1.239
GO molecular function 1.961 1.691 0.862 1.149 0.991
UniProt coding sequence diversity 0.369 0.741 2.008 1.299 2.609
UniProt disease 0.151 0.235 1.556 1.411 2.196
UniProt domain 0.695 1.272 1.830 1.271 2.325
UniProt ligand 1.006 0.889 0.884 1.168 1.033
UniProt PTM 1.343 1.778 1.324 2.050 2.715
Mean 1.340 1.379 1.863
std. err. 0.154 0.101 0.248
p-value 0.032 0.052
The mean numbers of annotation assignments for the PDB US non-SG ensemble and the structures determined by PSI:Biology Partnerships are shown in the first
two columns respectively. The third column shows the ratios of these means. The average of the eight ratios is calculated for an overall mean ratio. A 1-tailed
unpaired t-test is performed to test the null hypothesis that the overall mean ratio is greater than 1 (p-value = 0.0317). In the fourth and fifth data columns, the
normalized means are shown, where the normalization is done by dividing by the rates of annotation assignments by their corresponding means for the entire
PDB for structures deposited during the relevant time frame (July 1, 2010 through February 28, 2013). A 1-tailed unpaired t-test is performed on the data sets to
test the null hypothesis that the average of the means for PSI:Biology Partnership structures is greater than that for the PDB US non-SG ensemble
(p-value = 0.0517).
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determines structures of associated with mitochondrion
[1,22]. Also prevalent are proteins that are alternatively
spliced. Such proteins are seen as a relative focus given
their importance in protein disorder [23], which is
relevant to PSI:Biology projects that involve signaling
networks [24]. We see that further review of relative
prevalence of the residue level annotations across the
range of highly specific functions further reveals details
of the relative focus of the PSI:Biology Partnerships.
Conclusions
There are two major findings from these analyses. First,
PSI:Biology indeed has a higher focus on proteins docu-
mented as being biomedically relevant than PSI:1&2.
This finding validates the annotation rate metric is a
means to measure the impact of PSI:Biology with regard
to the numbers of structure to biological function con-
nections examined. The metric is complementary to
established metrics of the numbers of structures and the
corresponding publication record of the structures. Sec-
ond, there is clear evidence that PSI:Biology Partnerships
have determined structures that are found to have a
higher biomedical relevance than that found for US gen-
erated, non-structural genomics structures. As more
structures are determined through PSI:Biology Partner-
ships and more data is evaluated, we expect this trend to
become more apparent based on the many annotation
types analyzed.An inference of the second finding is that PSI:Biology
Partnerships provide an added value towards the goals
of PSI:Biology with regard to the resultant biological
relevance of the determined structures. We interpret
the result as evidence that PSI:Biology Partnerships
are focusing on the determination of protein struc-
tures for which there is a higher interest to the
biomedical community as judged through the repre-
sentative annotation types. These representative anno-
tations are based on the UniProt keyword system and
based on the system developed by UniProt to identify
different residue level assignments of function. Through
the elucidation of structures, we see the team-based PSI:
Biology Partnerships as tying together the varied func-
tional information of proteins that have high biomedical
relevance.
We assess that the added value of the PSI:Biology Part-
nerships is something that has not previously been
quantified, and represents some of the progress toward
the goals of PSI:Biology. The NIH’s implementation of
peer-reviewed structural projects that involve the forma-
tion of well established collaborations between structural
genomics centers and biomedical scientists in the com-
munity are seen as providing a viable means to achieve
more valuable structures. We see that the annotation
metric can be used to monitor the progress towards the
goals of PSI:Biology. In particular we see the metric as a
means to quantify the added value and benefits of the














































Figure 4 Ratios of rates of UniProt annotation assignments
per residue for PSI:Biology Partnerships structures versus
non-structural genomics structures in the PDB. Asterisks indicate
the rates that are statistically different between the sets based on a
Student’s t-test (p-value ≤ 0.05). A ratio greater than 1 indicates
that on average there are more assignments per residue for that
annotation in structures from PSI:Biology Partnerships than from
PDB US non-SG structures. Data for the plot is available in
Additional file 1: Table S4.
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projects based on the annotation rates, a website with
interactive charting is available [25]. The site describes
the datasets used in the study in interactive form, and it
provides access to current updates of the annotations
across all structures in the PDB. A corresponding weekly




The first step in the data assembly was to review bio-
medical databases that annotate proteins and decide
which annotations therein to use in the study. All re-
sources were required to have an open-source policy of
freely available information to the scientific community.
We identified assignments of annotations that can
pertain to more than one protein such that none of theassignments used were specific to a single protein. Dif-
ferent proteins are defined as having a different primary
accession code in UniProt. Annotations from a specific
resource or subcategory of a specific resource were
grouped as annotation types. A list of 43 annotation
types that were identified is given in Additional file 1:
Table S5.
Assignments of annotations were mapped to protein
structures based on UniProt accession code correspon-
dences for each protein structural chain. Information
provided through UniProt data files and the SBKB were
utilized. In addition, information was directly extracted
from BioCyc [26], HumanCyc, NCI pathway [18], INOH
pathway [27], CellMap pathway, ChEBI ligand [28], RGD
[29], MGI [30], and OMIM [31]. We used from RGD
disease ontology (rdo) and pathway (pw) information for
rat, human, and mouse. The MGI database was used to
obtain mammalian phenotype information for mouse
proteins. Phenotype information was used from OMIM.
As a representative group of annotation types, we used
eight UniProt keyword categories. These keywords were
viewed as covering a wide variety of annotations while
remaining relatively independent with respect to the in-
formation that they provide. The UniProt keyword cat-
egory called developmental stage was not used due to
the use of non-standardized text descriptions instead of
keyword assignments in some cases, and due to the
relative scarcity of these annotations. The keywords of
technical terms were not used as these can refer to the
experimental system in which the protein was studied
rather than a functional attribute of a protein.
A refinement of the keyword system for our purpose was
to substitute the corresponding GO terms for the three
keyword categories in UniProt– biological process, molecu-
lar function, and cellular component. The UniProt keyword
entries are made to be different and complementary to GO
terms in many cases, but there are significant synonymous
cross-references as reflected in the mapping files. The
choice to use GO terms was primarily based on the fact
that not only are GO terms annotated manually and elec-
tronically by a specialized group of UniProt curators, but
also manually by approximately 36 supplemental external
groups as part of the GO Consortium [32]. We also see that
GO annotations in UniProt are generally limited to specific
terms at the lowest leaves of the GO hierarchy. This has
been verified by UniProt staff through a personal commu-
nication. We rely also on mappings between GO terms and
structures from the SIFTs project [33], which adds another
layer of review for these annotations.
Assignments of annotations of residues were taken
from sequence annotation features as provided through
UniProt. For the purposes here, only those annotation
assignments that described as naturally occurring func-
tions were used. In total, 29 types of annotation
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tures were obtained. A list of the types of annotations
used can be found in Additional file 1: Table S6.
The residue specific annotations from UniProt were
mapped to those residues that were found within the
region with a determined structure, and annotations
outside these regions were not considered further. Map-
ping was done by using the information in the UniProt
flat files that describe the functions of each residue. The
information on the residue number correspondences
between the UniProt sequence files and the PDB coordin-
ate files were provided through the SIFTs project [33]. We
used the mapping files see which annotations fell within
the region of the protein with a determined structure.
Data sets
Protein structures deposited to the PDB were separated
into three discrete data sets for comparison – PSI:1&2,
PSI:Biology, and PDB US non-SG. The PSI:1&2 set
(5138 structures in total) combined all structures deter-
mined during the first 2 phases of the PSI. PSI:Biology
(1017 structures in total) contained all structures consid-
ered part of the third phase of the PSI. Any structures
from the PSI projects that had multiple projects attrib-
uted to them, for example due to being studied at differ-
ent structural genomics centers, were assigned to their
earliest associated project. This was done to eliminate
mislabeling protein structures that were determined in
either PSI:1 or PSI:2 but subsequently have had a func-
tional assay performed on them during PSI:Biology.
The third data set, PDB US non-SG (5613 structures),
was comprised of US-only structures in the PDB depos-
ited during the PSI:Biology time period, excluding those
determined by structural genomics programs. We de-
fined a PSI:Biology time period as structures deposited
to the PDB from July 1, 2010 through February 28, 2013.
Structures in the PSI:Biology project were separated into
subsets based on their target categories as described in
the TargetTrack database [34,35]. PSI:Biology Partner-
ship structures were chosen as the subset of PSI:Biology
for a comparison to the PDB US non-SG data set. Of the
1017 structures determined in PSI:Biology as a whole,
there were 117 protein structures identified as resulting
from PSI:Biology Partnerships.
Data analyses
Each protein structure was associated with a UniProt
accession code using information from SIFTS (5). Chimeric
proteins (those protein structures that are associated with
more than one UniProt accession) were removed from the
data sets. The number of unique UniProt accession codes
for each data set was 4444, 790, 81, and 2624 for PSI:1&2,
PSI:Biology, PSI:Biology Partnerships, and PDB US non-SG
respectively.The rate, or mean numbers, of annotations per protein
structure for each data set were calculated. The sum of
the number of unique annotations was divided by the
number of associated unique UniProt accession codes.
For the residue level annotation analyses, the total num-
ber of residues for each project was split into groups of
250 residues, which was the average length of all the
structures studied. There were 3842 groups for PSI:1&2,
815 groups for PSI:Biology, 62 groups for PSI:Biology
Partnerships, and 2947 groups for the PDB US non-SG
ensemble. The rates per residue of each sequence feature
for residue level annotations were calculated by dividing
the number of instances found per each group of 250
residues by 250. The average across all the groups of 250
for each project was obtained.
The rates of annotation for the protein level assign-
ments and the residue level assignments were compared
between data sets. Student’s t-tests were conducted to
show which annotation types had significantly different
values between the data sets. For the comparison be-
tween the set of PSI:Biology Partnership structures to
the set of PDB US non-SG structures, the average of the
mean ratios of the annotation rates at the protein level
across the representative group of annotation types
based on the UniProt keyword system were tested to be
greater than 1. The t-statistic was calculated by t = (x’ – 1) /
SE where x’ is the average of the means and SE is the asso-
ciated standard error. The mean numbers of annotations
per protein for the representative annotation types (UniProt
keywords combined with GO terms as described above)
were also normalized to the mean for the given category as
obtained for the entire PDB over the time frame of PSI:
Biology. That time frame was July 1, 2010 to February 28,
2013. A 1-tailed unpaired t-test with the null hypothesis
that the average normalized values across the annotation
types for the two groups of structures was conducted.
Additional file
Additional file 1: Table S1. Mean number of annotations per PSI:
Biology and PSI:1&2 proteins across varied biomedical resources. Table
S2. Mean number of UniProt sequence annotations per residue for PSI:
Biology and PSI:1&2 structures. Table S3. Mean number of annotations
per PSI:Biology Partnership protein and per PDB US non-SG protein
across resources. Table S4. Mean number of UniProt sequence
annotations per residue for PSI:Biology Partnership and PDB US non-SG
structures. Table S5. List of the 43 annotation types used in the analysis.
Table S6. List of the 29 sequence annotations used in the residue level
analysis. Table S7. Mean number of annotations per protein for eight
UniProt keyword annotation types.
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